Both preclinical studies demonstrate that ISL could inhibit TGF-β/Smad-induced endometrial cancer cell migration through reducing p-Smad2/3 and TWIST1/2 expression, subsequently decreasing N-cadherin, vimentin, α-SMA while increasing E-cadherin protein expression. Here, SMAD2 is linked to endometrial cancer.